Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
Octreotide is a first-generation somatostatin analog that has been used for 40 years for the medical treatment of acromegaly, both after neurosurgical intervention and as first-line treatment. The frequency of biochemical control against the background of extended-acting octreotide varies from 25 to...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2022-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6942 |
| _version_ | 1827961784337694720 |
|---|---|
| author | I. A. Ilovayskaya |
| author_facet | I. A. Ilovayskaya |
| author_sort | I. A. Ilovayskaya |
| collection | DOAJ |
| description | Octreotide is a first-generation somatostatin analog that has been used for 40 years for the medical treatment of acromegaly, both after neurosurgical intervention and as first-line treatment. The frequency of biochemical control against the background of extended-acting octreotide varies from 25 to 56% depending on growth hormone and IGF-1 levels at the disease debut, presence of previous surgery, patient gender and age, treatment compliance and the dose of octreotide used. Longterm clinical experience with prolonged-acting octreotide demonstrates that more than half of patients require an increase in dosage to 30 mg or higher. If during treatment with Octreotide in a dose of 30 mg for 3 months there is no normalization of IGF-1 level, but there was a decrease of 50% or more of the initial level, further dose increase to 40 mg is possible, because this increases the effectiveness of treatment without increasing the frequency of side effects. Foreign researchers have shown that high doses of Octreotide (60 mg every 28 days) can improve biochemical control in patients who have not fully responded to therapy with doses of 30–40 mg of extended-acting Octreotide. Further studies are needed to determine the optimal dose of prolonged octreotide in acromegaly therapy, both at the start of treatment and during treatment. Management of patients by a team of specialists involved in the treatment of pituitary tumors will allow faster achievement of biochemical control of acromegaly. |
| first_indexed | 2024-04-09T16:31:59Z |
| format | Article |
| id | doaj.art-92cbb8595a584ee78ffa330360524328 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:31:59Z |
| publishDate | 2022-06-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-92cbb8595a584ee78ffa3303605243282023-04-23T06:57:03ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902022-06-0101014815210.21518/2079-701X-2022-16-10-148-1526223Octreotide in the treatment of acromegaly – the possibilities of high-dose therapyI. A. Ilovayskaya0Moscow Regional Research and Clinical Institute named after M.F. VladimirskiyOctreotide is a first-generation somatostatin analog that has been used for 40 years for the medical treatment of acromegaly, both after neurosurgical intervention and as first-line treatment. The frequency of biochemical control against the background of extended-acting octreotide varies from 25 to 56% depending on growth hormone and IGF-1 levels at the disease debut, presence of previous surgery, patient gender and age, treatment compliance and the dose of octreotide used. Longterm clinical experience with prolonged-acting octreotide demonstrates that more than half of patients require an increase in dosage to 30 mg or higher. If during treatment with Octreotide in a dose of 30 mg for 3 months there is no normalization of IGF-1 level, but there was a decrease of 50% or more of the initial level, further dose increase to 40 mg is possible, because this increases the effectiveness of treatment without increasing the frequency of side effects. Foreign researchers have shown that high doses of Octreotide (60 mg every 28 days) can improve biochemical control in patients who have not fully responded to therapy with doses of 30–40 mg of extended-acting Octreotide. Further studies are needed to determine the optimal dose of prolonged octreotide in acromegaly therapy, both at the start of treatment and during treatment. Management of patients by a team of specialists involved in the treatment of pituitary tumors will allow faster achievement of biochemical control of acromegaly.https://www.med-sovet.pro/jour/article/view/6942acromegalyoctreotidelanreotidebiochemical controlhigh doses |
| spellingShingle | I. A. Ilovayskaya Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy Медицинский совет acromegaly octreotide lanreotide biochemical control high doses |
| title | Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy |
| title_full | Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy |
| title_fullStr | Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy |
| title_full_unstemmed | Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy |
| title_short | Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy |
| title_sort | octreotide in the treatment of acromegaly the possibilities of high dose therapy |
| topic | acromegaly octreotide lanreotide biochemical control high doses |
| url | https://www.med-sovet.pro/jour/article/view/6942 |
| work_keys_str_mv | AT iailovayskaya octreotideinthetreatmentofacromegalythepossibilitiesofhighdosetherapy |